-
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within its corporate structure. The company’s sub-subsidiary, China Resources Kunming Shenghuo Pharmaceutical CO., Ltd., also known as CR Sanjiu (SHE: 000999), is poised to sell its 51% stake in Shenghuo to another subsidiary of CR Pharma,…
-
CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million
•
China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999), has announced its intention to conditionally purchase a substantial 28% stake in fellow Chinese firm Tasly Pharmaceuticals (SHA: 600535). The transaction involves the acquisition of 418,306,002 shares, with a proposed consideration of RMB 14.85 per share, culminating in a total deal value…
-
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
•
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has entered into a partnership with CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company specializing in treatments for cardiovascular and cerebrovascular diseases and endocrine disorders. Under this strategic alliance, ClouDr will serve as the general agent…
-
Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China
•
Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned pharmaceutical company, CR Sanjiu (SHE: 000999). This collaboration aims to enhance the reach of Stada’s cough and cold brands across hospital, pharmacy, and e-commerce channels in China. Key Brands Included in the Partnership The brands…
